International Biotechnol... Share Discussion Threads

[limpsfield chartist] 06/7/2000 15:49

No mention on these for a while and they have been moving quite nicely.

Looks positive for a run back up to the 350 levels from here. They have short
term (but should be good) support around the 250 level - if they were to slip
much below here I would be worried. Below 220 and I would think about getting
out. But they still look positive for me. Any deep deep weakness I would expect
to be halted ahead of 165/180 levels - a retracement to here would be seen as a
buying opportunity.

But on the face of things at the moment I do not think we are going to see a
pullback of this size and I expect the uptrend to continue.

LC

[juzzle] 24/5/2000 14:35

The idea of voting for a wind-up order is not going to win much support among investors sitting on substantial losses surely? Especially if managers can point to a large part of the drop being sector-specific rather than specific to IBT. The gain to be had from cashing in the trust is a pittance compared with the falls that holders have seen, and by the time it all went through the price is quite likely to have crept up by a greater amount. Price today might reflect excitement at a possible winding-up, but if holders start selling rather than being locked into such a process for so little gain the effect will be negative I would have thought.

[analyst] 24/5/2000 09:30

What's all this about then??


RNS Number:1133L
Intl. Biotechnology Trust PLC
24 May 2000


International Biotechnology Trust plc

The Board of International Biotechnology Trust plc
received on 22nd May 2000 a requisition from a
shareholder, holding some 10.06 per cent of the issued
share capital, requesting that the Directors convene an
extraordinary general meeting of the Company. The
principal business of this meeting is to consider a
resolution that the Directors should, within two months
of the EGM, put proposals to shareholders for a
reorganisation or reconstruction of the Company that
would enable shareholders to realise the whole of their
investment at a price related to net asset value.
Resolutions to remove three of the Directors are also to
be considered.

The Board has met to consider this requisition and will
be writing to shareholders shortly with its view on these
proposals.

Enquiries:
Peter Moorhouse/
Melville Trimble Merrill Lynch 020 7772 1000
Sue Charles HCC de Facto 020 7496 3312

[dil] 23/3/2000 22:47

I take the Michael Walters view that on a one year plus outlook this trust looks good value and an ideal way to play the bio's for those without specific knowledge of the industry.
Got a few tucked away in the pension.

Dil

[pommy] 23/3/2000 11:56

Damm I cant get the RNS story to format properly

[pommy] 23/3/2000 11:50

Here is the difference between the value on 15th March and last night of the top 10 holdings of the IBT as per the RNS release on 20th March. Now can someone explain why the shareprice is still the same as it was on 15th March!!






Value 15/3


Price 15/3

X-Rate

15/3 in £

Shares 15/3

Bid

Value


TGEN

35,811,962

11.94%

12.50

1.58

7.91

4526631.997

13.625

61675360.96


RZYM

27,236,918

9.08%

33.00

1.58

20.89

1304070.619

29.125

37981056.79


ANPI

24,883,961

8.30%

57.25

1.58

36.23

686753.8582

46.750

32105742.87


CTIC

20,732,565

6.91%

24.00

1.58

15.19

1364893.863

23.000

31392558.84


ONXX

19,355,856

6.45%

22.63

1.58

14.32

1351403.114

17.000

22973852.95


CVAS

16,434,334

5.48%

11.88

1.58

7.52

2185711.088

12.313

26911567.77


BII-L

11,692,099

3.90%

4.13

1

4.13

2831016.707

3.900

11040965.16


OSIP

6,459,896

2.15%

20.31

1.58

12.85

502542.3772

20.000

10050847.54


EPMN

4,539,421

1.51%

15.25

1.58

9.65

470313.7823

11.938

5614370.776


CEN-L

4,456,081

1.49%

1.02

1

1.02

4368706.863

1.050

4587142.206





1.58



























Total

171,603,093







244,333,466






Heres the RNS news Article:



RNS Number:5647H
Intl. Biotechnology Trust PLC
20 March 2000


For more information please contact:

Jeremy Curnock Cook, Director Sue Charles/Katja Stout
International Biotechnology Trus t plc HCC.De Facto Group plc
Tel:[phone] Tel:+ 44 (0) 20 7496 3300
E-mail: [e-mail] E-mail: [e-mail]

BIOTECH SECTOR PROVIDES RETURNS ND NEW INVESTMENT OPPORTUNITIES FOR
INTERNATIONAL BIOTECHNOLOGY TRUST

IBT divests from Medarex and MorphoSys with uplifts of 915% and 1469%
respectively and invests in Canadian-based AnorMED

March 20, 2000 - London, UK - International Biotechnology Trust (IBT) announced
today that it has made significant returns from its two recent divestments from
Medarex and MorphoSys. Uplifts in the value o IBT's investments were
respectively 915% and 1,469% with returns on investment of 73% and 185% per
annum. These returns are a reflection of IBT's good stock selection and of the
sharp rise in share prices in the sector over the quarter - in particular for
genomics and antibody companies.

IBT uses returns on investments to reinvest in new companies. In recent weeks
IBT has invested in publicly- quoted Canadian-based AnorMED Inc., in which it
made a #1.74 million (CAD 3,98 million) investment. AnorMED discovers and
develops therapeutic and diagnostic applications of metal complexes and meta l
binding compounds with emphasis on life threatening disease and acute
treatments. IBT has also made a follow-on investment in existing portfolio
company, Biocompatibles International plc, investing #1 million. These are in
addition to the recent investments announced in OSI Pharmaceuticals and Axxima.

Jeremy Curnock Cook, Director of IBT, commented 'We are extremely pleased that
our stock pic ks in antibody-based therapeutic companies have proved so lucrative
and that the timing of our divestments has rewarded our shareholders with
substantial returns.

He continued 'We are also pleased to be making a second investment in Canada,
following the investment in Angiotech in 1997. AnorMED has a strong pipeline,
is well partnered and compared to the average market cap of a US company with a
Phase III product, is undervalued.'

IBT's timing for divestment reflects the investment strategy laid out by the
fund - that is to invest typically for three to five years, and to choose a time
for ivestment that meets the criteria for return. In the case of both Medarex
and MorphoSys, target for returns was significantly exceeded.

IBT invested US$5 million as the lead investor in a US$11 mil lion placing of 2.2
million Medarex shares in November 1995. Mederex develops antibody-based
therapeutics to fight life threatening and debilitating diseases. The fund
invested US$5million in a US$1 .5 million private placement for MorphoSys, in
July 1997. In March 1999, MorphoSys completed a successful Initial Public
Offering on the German Neuer Markt raising $28 million. MorphoSys develops a nd
applies technologies that accelerate drug discovery and target characterisation
based on combinatorial chemistry. Both of these companies have performed
extremely well, as the genomics and antibod -based therapeutics companies have
out-performed the rest of the biotech sector.

IBT's Top 10 core holdings as at 15th March 2000 were:

Value Prop ortion of NAV
#000 as at 15th March 2000

Targeted Genetics Corporations 35,811,962 11.94%
Ribozyme Pharmaceuticals Inc 27,2 6,918 9.08%
Angiotech Pharmaceuticals Inc 24,883,961 8.30%
Cell Therapeutics Inc 20,732,565 6.91%
Onyx Pharmaceuticals 19,355,856 6.45%
Corvas International Inc. 16,434,334 5.48%
Biocompatibles International plc 11,692,099 3.90%
OSI Pharmaceuticals Inc. 6,459,896 .15%
Epimmune Inc 4,539,421 1.51%
CeNeS Pharmaceuticals plc 4,456,081 1.49%

IBT is the first investment trust on the London Stock Exchange o ffering exposure
to biotechnology stocks globally. IBT's investment strategy is to invest in
maturing biopharmaceutical companies in the USA, UK, Europe and Canada that have
significant potential to evelop important new drugs, or to improve healthcare
provision through innovative technologies or services. Investments are usually
held for the medium term, with a focus on capital growth.

Further information on IBT at www.internationalbiotrust.com

Issued by International Biotechnology Trust plc and approved by Rothschild Asset
Management, which is regulated by IMRO. As IBT invests in the bi technology
sector, investments in IBT should be regarded both as long term and as carrying
a high level of financial risk. Accordingly share value may fall as well as
rise and investors may not get back the amount invested.

Notes to editors

1. International Biotechnology Trust plc

www.internationalbiotrust.com

International Biotechnology Trust PLC (IBT) was launched to take advantage of
the nvestment opportunities arising in mid-stage life science companies, with
emphasis on investing a larger amount in relatively fewer companies, and
involving a close working relationship with investee companies through the
provision of strategic management support and sector expertise.

International Biotechnology Trust - Key Data
- Founded in 1994
- #299.9 million net asset value of investment at 15th March 2000
- Listed on London Stock Exchange (IBT.L)
- Invests primarily in mid-stage biotechnology companies
- Investment criteria
- sound technology platform
- under-resourced
- good pro spects for commercialisation
- Further financing may be invested where appropriate
- Strategic support and management development provided
- 18 core investments
- 12 in US, 3 in UK, 1 in Germany, 2 in Canada

2. AnorMED Inc.

www.anormed.com

AnorMED Inc. discovers and develops therapeutic and diagnostic applications of
metal complexes and metal binding compounds with emphasis on life threate ning
disease and acute treatments.

The AnorMED team has an outstanding success record discovering new compounds for
clinical development. The company's strategy is to progress its portfolio of
promi ing lead drug candidates through early stage clinical trials. Once
efficacy in patients is established, AnorMED will seek out licensing and/or
corporate partnerships for these areas.

The company's growth plans include taking products further down the development
path toward regulatory approval to obtain their full commercial potential.

END
MSCEAFDEALLEEFE

[camel] 16/2/2000 18:15

Any comments on its movement ?